✦ LIBER ✦

Human antitransforming growth factor β2 monoclonal antibody—a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical study

✍ Scribed by Dilani Siriwardena; Peng T Khaw; Anthony J King; Mark L Donaldson; Barry M Overton; Clive Migdal; M.Francesca Cordeiro

Book ID: 117327661
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 119 KB
Volume: 109
Category: Article
ISSN: 0161-6420
DOI: 10.1016/s0161-6420(01)00997-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human anti–transforming grow

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Golimumab, a new human tumor necrosis fa

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four–week efficacy and safety results of a randomized, placebo-controlled study

✍ Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G. Krueger; Dafna Gladman; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Erratum: Golimumab, a new human tumor ne

Erratum: Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four–week efficacy and safety results of a randomized, placebo-controlled study

✍ Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G. Krueger; Dafna Gladman; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB 👁 1 views

Double-Blind, Placebo-Controlled, Multic

Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast Cancer

✍ Guarneri, V.; Generali, D. G.; Frassoldati, A.; Artioli, F.; Boni, C.; Cavanna, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 157 KB

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views